Stem definition | Drug id | CAS RN |
---|---|---|
angiotensin II receptor antagonists, antihypertensive (non-peptidic) | 1481 | 138402-11-6 |
Dose | Unit | Route |
---|---|---|
0.15 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.08 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 10 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 70 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.94 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.10 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 14 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 30, 1997 | FDA | SANOFI AVENTIS US |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute kidney injury | 534.85 | 10.19 | 954 | 54932 | 252914 | 53040266 |
Hyponatraemia | 456.09 | 10.19 | 565 | 55321 | 108042 | 53185138 |
Neurologic neglect syndrome | 238.63 | 10.19 | 76 | 55810 | 1099 | 53292081 |
Carotid artery thrombosis | 235.09 | 10.19 | 76 | 55810 | 1156 | 53292024 |
Personality disorder | 199.76 | 10.19 | 94 | 55792 | 4037 | 53289143 |
Adjustment disorder | 198.35 | 10.19 | 75 | 55811 | 1848 | 53291332 |
Hemiplegia | 171.36 | 10.19 | 105 | 55781 | 7695 | 53285485 |
Hyperkalaemia | 161.41 | 10.19 | 239 | 55647 | 54017 | 53239163 |
Lactic acidosis | 148.38 | 10.19 | 189 | 55697 | 37064 | 53256116 |
Affect lability | 132.75 | 10.19 | 96 | 55790 | 9279 | 53283901 |
Rheumatoid arthritis | 125.83 | 10.19 | 88 | 55798 | 314443 | 52978737 |
Fall | 118.16 | 10.19 | 709 | 55177 | 357731 | 52935449 |
Sensory loss | 116.64 | 10.19 | 83 | 55803 | 7822 | 53285358 |
Drug ineffective | 116.24 | 10.19 | 453 | 55433 | 816792 | 52476388 |
Motor dysfunction | 106.13 | 10.19 | 80 | 55806 | 8238 | 53284942 |
Pain | 100.53 | 10.19 | 301 | 55585 | 588097 | 52705083 |
Aphasia | 99.39 | 10.19 | 141 | 55745 | 30637 | 53262543 |
Maternal exposure during pregnancy | 89.48 | 10.19 | 26 | 55860 | 155613 | 53137567 |
Eating disorder | 89.14 | 10.19 | 97 | 55789 | 16100 | 53277080 |
Treatment failure | 88.96 | 10.19 | 14 | 55872 | 128389 | 53164791 |
Renal failure | 88.32 | 10.19 | 299 | 55587 | 118153 | 53175027 |
Coordination abnormal | 86.56 | 10.19 | 83 | 55803 | 11868 | 53281312 |
Drug interaction | 85.42 | 10.19 | 454 | 55432 | 218875 | 53074305 |
Hypoglycaemia | 81.95 | 10.19 | 187 | 55699 | 58826 | 53234354 |
Hypotension | 81.28 | 10.19 | 499 | 55387 | 253577 | 53039603 |
Hemiparesis | 80.87 | 10.19 | 106 | 55780 | 21369 | 53271811 |
Muscle spasticity | 79.85 | 10.19 | 96 | 55790 | 17742 | 53275438 |
Therapeutic product effect decreased | 75.97 | 10.19 | 19 | 55867 | 125636 | 53167544 |
Contraindicated product administered | 75.52 | 10.19 | 24 | 55862 | 135605 | 53157575 |
Sinus bradycardia | 74.41 | 10.19 | 84 | 55802 | 14517 | 53278663 |
Glossodynia | 74.03 | 10.19 | 9 | 55877 | 100282 | 53192898 |
Systemic lupus erythematosus | 73.84 | 10.19 | 20 | 55866 | 125394 | 53167786 |
Drug hypersensitivity | 70.94 | 10.19 | 105 | 55781 | 265137 | 53028043 |
Blood pressure increased | 70.62 | 10.19 | 313 | 55573 | 140166 | 53153014 |
Hand deformity | 69.56 | 10.19 | 5 | 55881 | 84844 | 53208336 |
Hypertension | 64.19 | 10.19 | 430 | 55456 | 225001 | 53068179 |
Synovitis | 63.90 | 10.19 | 17 | 55869 | 107876 | 53185304 |
Cerebrovascular accident | 61.14 | 10.19 | 245 | 55641 | 104929 | 53188251 |
Bradycardia | 60.74 | 10.19 | 188 | 55698 | 70868 | 53222312 |
Hypertensive crisis | 58.37 | 10.19 | 74 | 55812 | 14432 | 53278748 |
Blood pressure systolic increased | 57.41 | 10.19 | 119 | 55767 | 35058 | 53258122 |
Off label use | 55.74 | 10.19 | 280 | 55606 | 471932 | 52821248 |
Hepatocellular injury | 55.61 | 10.19 | 107 | 55779 | 29879 | 53263301 |
Ischaemic stroke | 54.53 | 10.19 | 80 | 55806 | 17913 | 53275267 |
Atrial fibrillation | 54.01 | 10.19 | 246 | 55640 | 111406 | 53181774 |
Dysarthria | 53.50 | 10.19 | 126 | 55760 | 40442 | 53252738 |
Pemphigoid | 52.92 | 10.19 | 48 | 55838 | 6396 | 53286784 |
Confusional state | 52.60 | 10.19 | 366 | 55520 | 193855 | 53099325 |
Death | 48.56 | 10.19 | 201 | 55685 | 357031 | 52936149 |
Syncope | 48.52 | 10.19 | 239 | 55647 | 111754 | 53181426 |
Arthropathy | 47.30 | 10.19 | 47 | 55839 | 141406 | 53151774 |
Rhabdomyolysis | 47 | 10.19 | 126 | 55760 | 43797 | 53249383 |
Hypokalaemia | 46.93 | 10.19 | 213 | 55673 | 96304 | 53196876 |
Inappropriate antidiuretic hormone secretion | 46.07 | 10.19 | 67 | 55819 | 14884 | 53278296 |
Swelling | 46.03 | 10.19 | 81 | 55805 | 191024 | 53102156 |
Vertigo | 45.73 | 10.19 | 146 | 55740 | 55935 | 53237245 |
Alopecia | 44.33 | 10.19 | 114 | 55772 | 234469 | 53058711 |
Exposure during pregnancy | 43.48 | 10.19 | 40 | 55846 | 124820 | 53168360 |
Asthenia | 43.46 | 10.19 | 550 | 55336 | 343040 | 52950140 |
Cholestasis | 43.27 | 10.19 | 94 | 55792 | 28601 | 53264579 |
Dehydration | 42.47 | 10.19 | 312 | 55574 | 168098 | 53125082 |
Joint swelling | 39.90 | 10.19 | 120 | 55766 | 234518 | 53058662 |
Atrioventricular block first degree | 39.24 | 10.19 | 41 | 55845 | 6494 | 53286686 |
Shock haemorrhagic | 38.79 | 10.19 | 48 | 55838 | 9135 | 53284045 |
Product dose omission issue | 37.06 | 10.19 | 92 | 55794 | 191528 | 53101652 |
Pericarditis | 36.55 | 10.19 | 11 | 55875 | 64395 | 53228785 |
Infection | 36.26 | 10.19 | 79 | 55807 | 172126 | 53121054 |
Oedema peripheral | 36.22 | 10.19 | 304 | 55582 | 170483 | 53122697 |
Abdominal discomfort | 36.20 | 10.19 | 115 | 55771 | 220947 | 53072233 |
Therapeutic product effect incomplete | 36.19 | 10.19 | 26 | 55860 | 91758 | 53201422 |
Fear of eating | 35.79 | 10.19 | 14 | 55872 | 379 | 53292801 |
Arteriovenous fistula occlusion | 35.79 | 10.19 | 14 | 55872 | 379 | 53292801 |
Atrioventricular block complete | 35.64 | 10.19 | 43 | 55843 | 7972 | 53285208 |
Blue toe syndrome | 34.79 | 10.19 | 14 | 55872 | 409 | 53292771 |
Completed suicide | 34.71 | 10.19 | 57 | 55829 | 138144 | 53155036 |
Drug intolerance | 34.28 | 10.19 | 106 | 55780 | 205387 | 53087793 |
Product use issue | 32.84 | 10.19 | 60 | 55826 | 139524 | 53153656 |
Angioedema | 31.13 | 10.19 | 106 | 55780 | 41970 | 53251210 |
Muscular weakness | 30.72 | 10.19 | 196 | 55690 | 100796 | 53192384 |
Hepatic cytolysis | 29.80 | 10.19 | 39 | 55847 | 7846 | 53285334 |
Rash | 29.52 | 10.19 | 312 | 55574 | 445879 | 52847301 |
Tubulointerstitial nephritis | 29.51 | 10.19 | 58 | 55828 | 16446 | 53276734 |
Malaise | 29.08 | 10.19 | 531 | 55355 | 357086 | 52936094 |
Renal impairment | 28.05 | 10.19 | 166 | 55720 | 83152 | 53210028 |
Dysphagia | 27.68 | 10.19 | 167 | 55719 | 84230 | 53208950 |
Prothrombin time ratio decreased | 27.01 | 10.19 | 12 | 55874 | 450 | 53292730 |
Neurofibrosarcoma | 26.91 | 10.19 | 9 | 55877 | 153 | 53293027 |
Blood potassium increased | 26.39 | 10.19 | 58 | 55828 | 17783 | 53275397 |
Anuria | 26.33 | 10.19 | 47 | 55839 | 12393 | 53280787 |
Hypersensitivity | 25.87 | 10.19 | 123 | 55763 | 210542 | 53082638 |
Vascular purpura | 25.68 | 10.19 | 17 | 55869 | 1424 | 53291756 |
Blood pressure fluctuation | 25.05 | 10.19 | 88 | 55798 | 35382 | 53257798 |
Haematoma | 24.80 | 10.19 | 85 | 55801 | 33759 | 53259421 |
International normalised ratio increased | 24.40 | 10.19 | 107 | 55779 | 47654 | 53245526 |
Psoriatic arthropathy | 24.31 | 10.19 | 10 | 55876 | 48180 | 53245000 |
Sinus arrest | 24.11 | 10.19 | 18 | 55868 | 1826 | 53291354 |
Acidosis | 24.06 | 10.19 | 43 | 55843 | 11349 | 53281831 |
Febrile neutropenia | 23.89 | 10.19 | 46 | 55840 | 104890 | 53188290 |
Blood creatinine increased | 23.66 | 10.19 | 158 | 55728 | 82504 | 53210676 |
Meningorrhagia | 23.60 | 10.19 | 8 | 55878 | 142 | 53293038 |
Intestinal angioedema | 23.31 | 10.19 | 12 | 55874 | 627 | 53292553 |
Hypergammaglobulinaemia | 23.16 | 10.19 | 11 | 55875 | 482 | 53292698 |
Haemangioma congenital | 22.97 | 10.19 | 11 | 55875 | 491 | 53292689 |
Blood pressure inadequately controlled | 22.91 | 10.19 | 27 | 55859 | 4884 | 53288296 |
Anal polyp | 22.62 | 10.19 | 6 | 55880 | 43 | 53293137 |
Blood sodium decreased | 22.43 | 10.19 | 64 | 55822 | 23052 | 53270128 |
Injection site reaction | 22.20 | 10.19 | 13 | 55873 | 51153 | 53242027 |
Heart rate decreased | 22.19 | 10.19 | 87 | 55799 | 36860 | 53256320 |
Injection site erythema | 22.19 | 10.19 | 29 | 55857 | 77220 | 53215960 |
Sinusitis | 22.13 | 10.19 | 96 | 55790 | 168468 | 53124712 |
Toxicity to various agents | 22.12 | 10.19 | 137 | 55749 | 219461 | 53073719 |
Prevertebral soft tissue swelling of cervical space | 22.04 | 10.19 | 6 | 55880 | 48 | 53293132 |
Interstitial lung disease | 21.83 | 10.19 | 120 | 55766 | 58502 | 53234678 |
Discomfort | 21.60 | 10.19 | 42 | 55844 | 95430 | 53197750 |
Diabetic metabolic decompensation | 21.53 | 10.19 | 16 | 55870 | 1612 | 53291568 |
Cutaneous vasculitis | 21.42 | 10.19 | 25 | 55861 | 4476 | 53288704 |
Torsade de pointes | 21.22 | 10.19 | 44 | 55842 | 12961 | 53280219 |
Renin decreased | 21.21 | 10.19 | 7 | 55879 | 114 | 53293066 |
Hypochloraemia | 21.10 | 10.19 | 17 | 55869 | 1929 | 53291251 |
Eosinophilia | 20.64 | 10.19 | 59 | 55827 | 21276 | 53271904 |
Primary hyperaldosteronism | 20.33 | 10.19 | 6 | 55880 | 66 | 53293114 |
Botryomycosis | 20.22 | 10.19 | 5 | 55881 | 26 | 53293154 |
Dermatitis bullous | 20.12 | 10.19 | 33 | 55853 | 8130 | 53285050 |
Coronary artery disease | 19.49 | 10.19 | 78 | 55808 | 33359 | 53259821 |
Loss of consciousness | 19.46 | 10.19 | 194 | 55692 | 114018 | 53179162 |
Injection site pain | 19.24 | 10.19 | 58 | 55828 | 113333 | 53179847 |
Haemodialysis | 19.23 | 10.19 | 35 | 55851 | 9369 | 53283811 |
Milk-alkali syndrome | 19.12 | 10.19 | 11 | 55875 | 717 | 53292463 |
Fatigue | 19.04 | 10.19 | 602 | 55284 | 729904 | 52563276 |
Vulvar basal cell carcinoma | 18.95 | 10.19 | 5 | 55881 | 35 | 53293145 |
Blood aldosterone increased | 18.27 | 10.19 | 7 | 55879 | 179 | 53293001 |
Duodenal ulcer perforation | 18.24 | 10.19 | 7 | 55879 | 35176 | 53258004 |
Dizziness | 18.05 | 10.19 | 514 | 55372 | 371745 | 52921435 |
Electrolyte imbalance | 18.05 | 10.19 | 52 | 55834 | 18832 | 53274348 |
Hyperlactacidaemia | 18.00 | 10.19 | 18 | 55868 | 2707 | 53290473 |
Upper respiratory tract infection | 17.81 | 10.19 | 28 | 55858 | 69069 | 53224111 |
Histoplasmosis | 17.72 | 10.19 | 15 | 55871 | 1823 | 53291357 |
Irritable bowel syndrome | 17.67 | 10.19 | 12 | 55874 | 43620 | 53249560 |
Wound | 17.65 | 10.19 | 44 | 55842 | 91513 | 53201667 |
Abortion spontaneous | 17.37 | 10.19 | 14 | 55872 | 46621 | 53246559 |
Hepatitis | 17.36 | 10.19 | 76 | 55810 | 33818 | 53259362 |
Congenital musculoskeletal anomaly | 17.27 | 10.19 | 9 | 55877 | 482 | 53292698 |
Product use in unapproved indication | 17.27 | 10.19 | 60 | 55826 | 112229 | 53180951 |
Sebaceous gland infection | 17.22 | 10.19 | 6 | 55880 | 116 | 53293064 |
Cardiac failure | 17.22 | 10.19 | 151 | 55735 | 85693 | 53207487 |
Renal pain | 17.12 | 10.19 | 26 | 55860 | 6001 | 53287179 |
Reversible cerebral vasoconstriction syndrome | 17.03 | 10.19 | 16 | 55870 | 2229 | 53290951 |
Left atrial dilatation | 16.98 | 10.19 | 15 | 55871 | 1930 | 53291250 |
Blood pressure diastolic decreased | 16.77 | 10.19 | 47 | 55839 | 16756 | 53276424 |
Brucellosis | 16.63 | 10.19 | 5 | 55881 | 59 | 53293121 |
Myocardial infarction | 16.56 | 10.19 | 168 | 55718 | 99186 | 53193994 |
Sepsis | 16.53 | 10.19 | 88 | 55798 | 146341 | 53146839 |
Product substitution issue | 16.45 | 10.19 | 45 | 55841 | 15821 | 53277359 |
Arthralgia | 16.34 | 10.19 | 344 | 55542 | 439439 | 52853741 |
Incision site haemorrhage | 16.27 | 10.19 | 9 | 55877 | 544 | 53292636 |
Orthostatic hypotension | 16.23 | 10.19 | 68 | 55818 | 29685 | 53263495 |
Cardiac ventricular thrombosis | 16.18 | 10.19 | 9 | 55877 | 550 | 53292630 |
Impaired healing | 15.63 | 10.19 | 27 | 55859 | 64178 | 53229002 |
Adverse drug reaction | 15.53 | 10.19 | 20 | 55866 | 53605 | 53239575 |
Hospitalisation | 15.41 | 10.19 | 32 | 55854 | 70980 | 53222200 |
Emphysematous cystitis | 15.39 | 10.19 | 6 | 55880 | 161 | 53293019 |
Body temperature decreased | 15.14 | 10.19 | 45 | 55841 | 16582 | 53276598 |
Depression | 15.09 | 10.19 | 121 | 55765 | 182931 | 53110249 |
Electrocardiogram QT prolonged | 15.06 | 10.19 | 106 | 55780 | 56297 | 53236883 |
Intentional self-injury | 14.93 | 10.19 | 4 | 55882 | 25280 | 53267900 |
Pulmonary artery atresia | 14.92 | 10.19 | 4 | 55882 | 30 | 53293150 |
Jaundice | 14.79 | 10.19 | 67 | 55819 | 30246 | 53262934 |
Oliguria | 14.77 | 10.19 | 31 | 55855 | 9207 | 53283973 |
Enterococcal sepsis | 14.74 | 10.19 | 12 | 55874 | 1382 | 53291798 |
Intra-abdominal haematoma | 14.72 | 10.19 | 13 | 55873 | 1672 | 53291508 |
Device related infection | 14.65 | 10.19 | 3 | 55883 | 22783 | 53270397 |
Shock | 14.31 | 10.19 | 55 | 55831 | 23084 | 53270096 |
Sinus node dysfunction | 14.10 | 10.19 | 20 | 55866 | 4341 | 53288839 |
Electrocardiogram PR prolongation | 14.08 | 10.19 | 9 | 55877 | 710 | 53292470 |
Disease progression | 14.02 | 10.19 | 57 | 55829 | 101863 | 53191317 |
Wrong patient received product | 13.95 | 10.19 | 14 | 55872 | 2114 | 53291066 |
Retching | 13.93 | 10.19 | 39 | 55847 | 13894 | 53279286 |
Premature delivery | 13.85 | 10.19 | 5 | 55881 | 26099 | 53267081 |
Injection site pruritus | 13.68 | 10.19 | 14 | 55872 | 41575 | 53251605 |
Necrotising myositis | 13.68 | 10.19 | 7 | 55879 | 361 | 53292819 |
Disorientation | 13.61 | 10.19 | 79 | 55807 | 39280 | 53253900 |
Hypochromic anaemia | 13.45 | 10.19 | 13 | 55873 | 1876 | 53291304 |
Device dislocation | 13.44 | 10.19 | 4 | 55882 | 23593 | 53269587 |
Respiratory acidosis | 13.35 | 10.19 | 24 | 55862 | 6364 | 53286816 |
Malignant neoplasm progression | 13.31 | 10.19 | 35 | 55851 | 71506 | 53221674 |
Injection site swelling | 13.30 | 10.19 | 15 | 55871 | 42613 | 53250567 |
Pulmonary pain | 13.09 | 10.19 | 14 | 55872 | 2278 | 53290902 |
Skin sensitisation | 13.04 | 10.19 | 9 | 55877 | 807 | 53292373 |
Pneumonia | 13.00 | 10.19 | 326 | 55560 | 406843 | 52886337 |
Parotid gland enlargement | 12.95 | 10.19 | 9 | 55877 | 816 | 53292364 |
Musculoskeletal stiffness | 12.91 | 10.19 | 76 | 55810 | 123292 | 53169888 |
Drug ineffective for unapproved indication | 12.77 | 10.19 | 3 | 55883 | 20717 | 53272463 |
Pure white cell aplasia | 12.74 | 10.19 | 4 | 55882 | 55 | 53293125 |
Tendon injury | 12.72 | 10.19 | 12 | 55874 | 1680 | 53291500 |
Multiple sclerosis relapse | 12.71 | 10.19 | 17 | 55869 | 44836 | 53248344 |
Fundoscopy abnormal | 12.58 | 10.19 | 3 | 55883 | 13 | 53293167 |
Transient ischaemic attack | 12.55 | 10.19 | 72 | 55814 | 35653 | 53257527 |
Anaphylactic reaction | 12.43 | 10.19 | 104 | 55782 | 58222 | 53234958 |
Ascites | 12.38 | 10.19 | 14 | 55872 | 39721 | 53253459 |
Migraine | 12.34 | 10.19 | 43 | 55843 | 80374 | 53212806 |
Oropharyngeal swelling | 12.28 | 10.19 | 9 | 55877 | 887 | 53292293 |
Acute coronary syndrome | 12.27 | 10.19 | 31 | 55855 | 10393 | 53282787 |
Cerebral haemorrhage | 12.26 | 10.19 | 63 | 55823 | 29933 | 53263247 |
Subacute kidney injury | 12.23 | 10.19 | 3 | 55883 | 15 | 53293165 |
Rash morbilliform | 12.12 | 10.19 | 16 | 55870 | 3247 | 53289933 |
Drug resistance | 12.09 | 10.19 | 3 | 55883 | 19959 | 53273221 |
Anaemia | 12.02 | 10.19 | 377 | 55509 | 276341 | 53016839 |
Injection site bruising | 12.02 | 10.19 | 13 | 55873 | 37633 | 53255547 |
Haematoma muscle | 11.96 | 10.19 | 8 | 55878 | 682 | 53292498 |
Impaired work ability | 11.77 | 10.19 | 37 | 55849 | 14053 | 53279127 |
Peripheral swelling | 11.68 | 10.19 | 149 | 55737 | 205959 | 53087221 |
Blood immunoglobulin E increased | 11.53 | 10.19 | 13 | 55873 | 2242 | 53290938 |
Bronchopulmonary aspergillosis allergic | 11.49 | 10.19 | 10 | 55876 | 1262 | 53291918 |
Renal tubular necrosis | 11.45 | 10.19 | 32 | 55854 | 11387 | 53281793 |
Fibrous histiocytoma | 11.44 | 10.19 | 7 | 55879 | 511 | 53292669 |
Condition aggravated | 11.43 | 10.19 | 231 | 55655 | 296903 | 52996277 |
Physical assault | 11.42 | 10.19 | 9 | 55877 | 989 | 53292191 |
Optic nerve infarction | 11.37 | 10.19 | 3 | 55883 | 21 | 53293159 |
Localised oedema | 11.16 | 10.19 | 20 | 55866 | 5289 | 53287891 |
Respiratory tract infection | 11.14 | 10.19 | 11 | 55875 | 33213 | 53259967 |
Stomatitis | 11.07 | 10.19 | 59 | 55827 | 98099 | 53195081 |
Oral lichen planus | 11.06 | 10.19 | 7 | 55879 | 543 | 53292637 |
Subacute cutaneous lupus erythematosus | 11.02 | 10.19 | 13 | 55873 | 2355 | 53290825 |
Blood pressure decreased | 10.97 | 10.19 | 106 | 55780 | 61763 | 53231417 |
Ear pain | 10.93 | 10.19 | 9 | 55877 | 29664 | 53263516 |
Helicobacter infection | 10.88 | 10.19 | 15 | 55871 | 39054 | 53254126 |
Contraindicated product prescribed | 10.85 | 10.19 | 8 | 55878 | 796 | 53292384 |
Hepatorenal syndrome | 10.82 | 10.19 | 12 | 55874 | 2033 | 53291147 |
Drug abuse | 10.77 | 10.19 | 34 | 55852 | 65492 | 53227688 |
C-reactive protein abnormal | 10.63 | 10.19 | 7 | 55879 | 25863 | 53267317 |
Toxic skin eruption | 10.51 | 10.19 | 34 | 55852 | 13105 | 53280075 |
White blood cell analysis abnormal | 10.43 | 10.19 | 3 | 55883 | 30 | 53293150 |
Insulinoma | 10.38 | 10.19 | 4 | 55882 | 104 | 53293076 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute kidney injury | 295.96 | 10.83 | 916 | 39499 | 292552 | 32180559 |
Lactic acidosis | 120.85 | 10.83 | 177 | 40238 | 33359 | 32439752 |
Death | 114.07 | 10.83 | 188 | 40227 | 382329 | 32090782 |
Hyponatraemia | 97.22 | 10.83 | 256 | 40159 | 74257 | 32398854 |
Hyperkalaemia | 96.52 | 10.83 | 245 | 40170 | 69505 | 32403606 |
Oesophageal pain | 59.73 | 10.83 | 26 | 40389 | 778 | 32472333 |
Anorectal discomfort | 59.39 | 10.83 | 34 | 40381 | 1846 | 32471265 |
Hypoglycaemia | 59.20 | 10.83 | 175 | 40240 | 54207 | 32418904 |
Hypotension | 58.16 | 10.83 | 463 | 39952 | 215647 | 32257464 |
Drug abuse | 56.41 | 10.83 | 15 | 40400 | 80228 | 32392883 |
Off label use | 55.70 | 10.83 | 195 | 40220 | 306125 | 32166986 |
Bradycardia | 52.78 | 10.83 | 202 | 40213 | 71360 | 32401751 |
Completed suicide | 48.97 | 10.83 | 27 | 40388 | 92490 | 32380621 |
Eosinophilia | 48.13 | 10.83 | 100 | 40315 | 24858 | 32448253 |
Seronegative arthritis | 45.43 | 10.83 | 23 | 40392 | 974 | 32472137 |
Blood pressure increased | 45.22 | 10.83 | 207 | 40208 | 79147 | 32393964 |
Fractured coccyx | 45.17 | 10.83 | 14 | 40401 | 153 | 32472958 |
Syncope | 44.09 | 10.83 | 225 | 40190 | 89899 | 32383212 |
Presyncope | 41.49 | 10.83 | 76 | 40339 | 17225 | 32455886 |
Febrile neutropenia | 41.09 | 10.83 | 53 | 40362 | 119513 | 32353598 |
Blood pressure systolic increased | 39.94 | 10.83 | 75 | 40340 | 17321 | 32455790 |
Foetal exposure during pregnancy | 39.85 | 10.83 | 3 | 40412 | 41298 | 32431813 |
Drug ineffective | 39.57 | 10.83 | 297 | 40118 | 383180 | 32089931 |
N-terminal prohormone brain natriuretic peptide abnormal | 37.83 | 10.83 | 13 | 40402 | 201 | 32472910 |
Failure to suspend medication | 35.88 | 10.83 | 14 | 40401 | 315 | 32472796 |
Blood thyroid stimulating hormone abnormal | 35.40 | 10.83 | 13 | 40402 | 246 | 32472865 |
Pneumonia | 34.81 | 10.83 | 279 | 40136 | 354973 | 32118138 |
Treatment failure | 34.71 | 10.83 | 4 | 40411 | 39159 | 32433952 |
Pulmonary arterial pressure abnormal | 34.26 | 10.83 | 12 | 40403 | 197 | 32472914 |
Lipoma | 33.79 | 10.83 | 22 | 40393 | 1506 | 32471605 |
Electrocardiogram QRS complex abnormal | 32.50 | 10.83 | 13 | 40402 | 313 | 32472798 |
Eczema | 32.43 | 10.83 | 63 | 40352 | 14917 | 32458194 |
Brain natriuretic peptide abnormal | 31.28 | 10.83 | 13 | 40402 | 346 | 32472765 |
Oxygen saturation increased | 31.22 | 10.83 | 12 | 40403 | 259 | 32472852 |
Agranulocytosis | 30.91 | 10.83 | 81 | 40334 | 23396 | 32449715 |
Rhabdomyolysis | 30.85 | 10.83 | 165 | 40250 | 67100 | 32406011 |
Disease progression | 30.35 | 10.83 | 38 | 40377 | 86824 | 32386287 |
Blood creatinine increased | 30.31 | 10.83 | 214 | 40201 | 95918 | 32377193 |
Fall | 29.58 | 10.83 | 373 | 40042 | 195828 | 32277283 |
Lung diffusion test decreased | 28.95 | 10.83 | 15 | 40400 | 667 | 32472444 |
Congenital diaphragmatic anomaly | 28.61 | 10.83 | 7 | 40408 | 28 | 32473083 |
Tongue abscess | 28.46 | 10.83 | 5 | 40410 | 0 | 32473111 |
Renal failure | 28.21 | 10.83 | 273 | 40142 | 134205 | 32338906 |
Arrhythmia | 27.96 | 10.83 | 102 | 40313 | 35201 | 32437910 |
Dysgeusia | 27.61 | 10.83 | 82 | 40333 | 25449 | 32447662 |
Carotid arteriosclerosis | 27.61 | 10.83 | 17 | 40398 | 1056 | 32472055 |
Plasma cell myeloma | 27.44 | 10.83 | 19 | 40396 | 57595 | 32415516 |
Gastrointestinal motility disorder | 27.41 | 10.83 | 23 | 40392 | 2324 | 32470787 |
Hypoparathyroidism | 27.38 | 10.83 | 13 | 40402 | 478 | 32472633 |
Mycobacterium test positive | 27.35 | 10.83 | 12 | 40403 | 366 | 32472745 |
Drug interaction | 26.85 | 10.83 | 400 | 40015 | 217785 | 32255326 |
Pemphigoid | 26.78 | 10.83 | 42 | 40373 | 8394 | 32464717 |
Hypovolaemia | 26.54 | 10.83 | 43 | 40372 | 8834 | 32464277 |
Vomiting projectile | 25.64 | 10.83 | 14 | 40401 | 693 | 32472418 |
Left ventricular dilatation | 25.56 | 10.83 | 14 | 40401 | 697 | 32472414 |
Cerebrovascular accident | 24.82 | 10.83 | 188 | 40227 | 86132 | 32386979 |
Vestibular neuronitis | 24.43 | 10.83 | 9 | 40406 | 172 | 32472939 |
Product dose omission issue | 23.88 | 10.83 | 58 | 40357 | 102517 | 32370594 |
Pancreatitis acute | 23.37 | 10.83 | 81 | 40334 | 27254 | 32445857 |
Antiphospholipid antibodies positive | 22.89 | 10.83 | 10 | 40405 | 302 | 32472809 |
Wrong patient received product | 22.51 | 10.83 | 21 | 40394 | 2441 | 32470670 |
Sepsis | 22.03 | 10.83 | 112 | 40303 | 158722 | 32314389 |
Shock | 21.98 | 10.83 | 73 | 40342 | 24041 | 32449070 |
Tachyarrhythmia | 21.92 | 10.83 | 24 | 40391 | 3375 | 32469736 |
Anuria | 21.56 | 10.83 | 44 | 40371 | 10793 | 32462318 |
Left atrial dilatation | 21.16 | 10.83 | 18 | 40397 | 1854 | 32471257 |
Ear discomfort | 21.01 | 10.83 | 20 | 40395 | 2384 | 32470727 |
Rash maculo-papular | 20.55 | 10.83 | 79 | 40336 | 27943 | 32445168 |
Cholestasis | 20.47 | 10.83 | 77 | 40338 | 26956 | 32446155 |
Blood creatine phosphokinase increased | 20.47 | 10.83 | 111 | 40304 | 45365 | 32427746 |
Toxicity to various agents | 20.17 | 10.83 | 134 | 40281 | 177907 | 32295204 |
Preternatural anus | 20.09 | 10.83 | 7 | 40408 | 113 | 32472998 |
Acute pulmonary oedema | 19.83 | 10.83 | 35 | 40380 | 7706 | 32465405 |
Mucosal dryness | 19.63 | 10.83 | 14 | 40401 | 1113 | 32471998 |
Hypertension | 19.61 | 10.83 | 250 | 40165 | 131500 | 32341611 |
Malignant neoplasm progression | 19.38 | 10.83 | 43 | 40372 | 78453 | 32394658 |
Neutrophil count decreased | 19.37 | 10.83 | 18 | 40397 | 47121 | 32425990 |
White blood cell count decreased | 19.36 | 10.83 | 54 | 40361 | 91144 | 32381967 |
Procedural failure | 19.24 | 10.83 | 6 | 40409 | 67 | 32473044 |
Mental status changes | 19.12 | 10.83 | 12 | 40403 | 38325 | 32434786 |
Myopathy | 19.06 | 10.83 | 43 | 40372 | 11298 | 32461813 |
Renal haemorrhage | 19.01 | 10.83 | 15 | 40400 | 1390 | 32471721 |
Product use in unapproved indication | 18.99 | 10.83 | 51 | 40364 | 87153 | 32385958 |
Supraventricular extrasystoles | 18.92 | 10.83 | 22 | 40393 | 3303 | 32469808 |
SARS-CoV-2 sepsis | 18.89 | 10.83 | 7 | 40408 | 136 | 32472975 |
Dyslipidaemia | 18.78 | 10.83 | 32 | 40383 | 6851 | 32466260 |
Platelet count decreased | 18.75 | 10.83 | 76 | 40339 | 114515 | 32358596 |
Morganella infection | 18.69 | 10.83 | 10 | 40405 | 475 | 32472636 |
Diabetes mellitus inadequate control | 18.63 | 10.83 | 48 | 40367 | 13720 | 32459391 |
Hyperlactacidaemia | 18.61 | 10.83 | 21 | 40394 | 3053 | 32470058 |
Cerebral haematoma | 18.20 | 10.83 | 26 | 40389 | 4785 | 32468326 |
Tenoplasty | 18.06 | 10.83 | 4 | 40411 | 9 | 32473102 |
Melaena | 17.95 | 10.83 | 88 | 40327 | 34577 | 32438534 |
Muscle strain | 17.92 | 10.83 | 23 | 40392 | 3822 | 32469289 |
Lividity | 17.92 | 10.83 | 7 | 40408 | 158 | 32472953 |
Pseudoporphyria | 17.62 | 10.83 | 8 | 40407 | 265 | 32472846 |
Carcinoma in situ of skin | 17.57 | 10.83 | 6 | 40409 | 91 | 32473020 |
Hospitalisation | 17.54 | 10.83 | 21 | 40394 | 48950 | 32424161 |
Pruritus | 17.40 | 10.83 | 240 | 40175 | 128462 | 32344649 |
Toxic skin eruption | 17.30 | 10.83 | 42 | 40373 | 11572 | 32461539 |
Goitre | 17.27 | 10.83 | 15 | 40400 | 1589 | 32471522 |
Nephrectomy | 17.18 | 10.83 | 11 | 40404 | 732 | 32472379 |
Metabolic acidosis | 16.76 | 10.83 | 97 | 40318 | 40602 | 32432509 |
Therapeutic product effect incomplete | 16.73 | 10.83 | 16 | 40399 | 41325 | 32431786 |
Renal impairment | 16.54 | 10.83 | 181 | 40234 | 91791 | 32381320 |
Dizziness | 16.42 | 10.83 | 358 | 40057 | 209260 | 32263851 |
Atrial thrombosis | 16.37 | 10.83 | 16 | 40399 | 1971 | 32471140 |
Precancerous skin lesion | 16.36 | 10.83 | 10 | 40405 | 613 | 32472498 |
Conduction disorder | 16.35 | 10.83 | 16 | 40399 | 1974 | 32471137 |
Lung disorder | 16.29 | 10.83 | 84 | 40331 | 33670 | 32439441 |
Superficial spreading melanoma stage I | 16.15 | 10.83 | 4 | 40411 | 17 | 32473094 |
Neoplasm prostate | 16.10 | 10.83 | 7 | 40408 | 209 | 32472902 |
Myalgia | 16.08 | 10.83 | 163 | 40252 | 81067 | 32392044 |
Haematocrit increased | 16.05 | 10.83 | 15 | 40400 | 1748 | 32471363 |
Echinococciasis | 15.97 | 10.83 | 4 | 40411 | 18 | 32473093 |
Rectal haemorrhage | 15.94 | 10.83 | 90 | 40325 | 37333 | 32435778 |
Cardiac ablation | 15.91 | 10.83 | 10 | 40405 | 644 | 32472467 |
Enterocutaneous fistula | 15.90 | 10.83 | 11 | 40404 | 833 | 32472278 |
Sneezing | 15.64 | 10.83 | 24 | 40391 | 4707 | 32468404 |
Enterochromaffin cell hyperplasia | 15.46 | 10.83 | 4 | 40411 | 21 | 32473090 |
Haemochromatosis | 15.42 | 10.83 | 12 | 40403 | 1089 | 32472022 |
Drug dependence | 15.38 | 10.83 | 5 | 40410 | 23479 | 32449632 |
Periorbital haematoma | 15.25 | 10.83 | 8 | 40407 | 365 | 32472746 |
Dermatitis exfoliative | 15.17 | 10.83 | 31 | 40384 | 7613 | 32465498 |
Musculoskeletal discomfort | 15.09 | 10.83 | 29 | 40386 | 6811 | 32466300 |
Bronchial haemorrhage | 14.99 | 10.83 | 10 | 40405 | 713 | 32472398 |
Vascular purpura | 14.86 | 10.83 | 14 | 40401 | 1648 | 32471463 |
Drug resistance | 14.84 | 10.83 | 5 | 40410 | 22960 | 32450151 |
Eosinophilic pleural effusion | 14.83 | 10.83 | 7 | 40408 | 254 | 32472857 |
Blood lactic acid | 14.76 | 10.83 | 8 | 40407 | 390 | 32472721 |
Product substitution issue | 14.76 | 10.83 | 37 | 40378 | 10399 | 32462712 |
Oedema peripheral | 14.71 | 10.83 | 211 | 40204 | 113880 | 32359231 |
Bundle branch block left | 14.63 | 10.83 | 26 | 40389 | 5753 | 32467358 |
Drug hypersensitivity | 14.46 | 10.83 | 45 | 40370 | 73355 | 32399756 |
Hepatocellular injury | 14.37 | 10.83 | 66 | 40349 | 25252 | 32447859 |
Shock haemorrhagic | 14.29 | 10.83 | 37 | 40378 | 10608 | 32462503 |
Asthenia | 14.27 | 10.83 | 389 | 40026 | 235555 | 32237556 |
Respiratory failure | 14.05 | 10.83 | 77 | 40338 | 107105 | 32366006 |
Rheumatoid arthritis | 14.02 | 10.83 | 21 | 40394 | 44523 | 32428588 |
Inflammation | 14.01 | 10.83 | 64 | 40351 | 24429 | 32448682 |
Sedation | 13.92 | 10.83 | 3 | 40412 | 18523 | 32454588 |
Inflammatory marker increased | 13.88 | 10.83 | 20 | 40395 | 3709 | 32469402 |
Blood pressure inadequately controlled | 13.83 | 10.83 | 17 | 40398 | 2705 | 32470406 |
Blood creatine increased | 13.78 | 10.83 | 23 | 40392 | 4842 | 32468269 |
Granuloma | 13.76 | 10.83 | 17 | 40398 | 2718 | 32470393 |
Appetite disorder | 13.75 | 10.83 | 15 | 40400 | 2100 | 32471011 |
Blood osmolarity decreased | 13.64 | 10.83 | 9 | 40406 | 630 | 32472481 |
Interstitial lung disease | 13.62 | 10.83 | 132 | 40283 | 64869 | 32408242 |
Hepatitis | 13.62 | 10.83 | 62 | 40353 | 23631 | 32449480 |
Atrial fibrillation | 13.55 | 10.83 | 212 | 40203 | 116492 | 32356619 |
Renal cyst | 13.49 | 10.83 | 32 | 40383 | 8687 | 32464424 |
Acute coronary syndrome | 13.42 | 10.83 | 43 | 40372 | 13898 | 32459213 |
Myocardial infarction | 13.37 | 10.83 | 225 | 40190 | 125451 | 32347660 |
Actinic keratosis | 13.16 | 10.83 | 20 | 40395 | 3890 | 32469221 |
Injection site pain | 13.14 | 10.83 | 13 | 40402 | 33045 | 32440066 |
Extrasystoles | 13.05 | 10.83 | 20 | 40395 | 3917 | 32469194 |
Malignant melanoma stage I | 13.05 | 10.83 | 5 | 40410 | 107 | 32473004 |
Dyspnoea exertional | 13.01 | 10.83 | 88 | 40327 | 38873 | 32434238 |
Atrial flutter | 12.98 | 10.83 | 45 | 40370 | 15138 | 32457973 |
Thyroiditis | 12.80 | 10.83 | 14 | 40401 | 1966 | 32471145 |
Angioedema | 12.74 | 10.83 | 83 | 40332 | 36206 | 32436905 |
Hypergastrinaemia | 12.64 | 10.83 | 4 | 40411 | 47 | 32473064 |
Gastrointestinal tract mucosal pigmentation | 12.59 | 10.83 | 7 | 40408 | 359 | 32472752 |
Hypoxia | 12.50 | 10.83 | 29 | 40386 | 52103 | 32421008 |
Orthostatic hypotension | 12.49 | 10.83 | 64 | 40351 | 25586 | 32447525 |
Ventricular hypokinesia | 12.35 | 10.83 | 22 | 40393 | 4878 | 32468233 |
Hypertensive crisis | 12.20 | 10.83 | 31 | 40384 | 8786 | 32464325 |
Haemoglobin increased | 12.17 | 10.83 | 17 | 40398 | 3065 | 32470046 |
Product use issue | 12.15 | 10.83 | 30 | 40385 | 52747 | 32420364 |
Chronic kidney disease | 12.00 | 10.83 | 88 | 40327 | 39887 | 32433224 |
Spinal epidural haemorrhage | 11.88 | 10.83 | 4 | 40411 | 58 | 32473053 |
Obstruction | 11.85 | 10.83 | 13 | 40402 | 1832 | 32471279 |
Blood bicarbonate decreased | 11.80 | 10.83 | 15 | 40400 | 2469 | 32470642 |
Psychotic disorder | 11.76 | 10.83 | 7 | 40408 | 23013 | 32450098 |
Accidental death | 11.72 | 10.83 | 14 | 40401 | 2163 | 32470948 |
Medication error | 11.52 | 10.83 | 57 | 40358 | 22478 | 32450633 |
Coronary artery disease | 11.45 | 10.83 | 103 | 40312 | 49603 | 32423508 |
Inappropriate antidiuretic hormone secretion | 11.42 | 10.83 | 37 | 40378 | 12026 | 32461085 |
Concomitant disease progression | 11.36 | 10.83 | 15 | 40400 | 2563 | 32470548 |
Cytomegalovirus infection | 11.34 | 10.83 | 9 | 40406 | 25455 | 32447656 |
Foreign body in respiratory tract | 11.29 | 10.83 | 5 | 40410 | 156 | 32472955 |
Pancreatic carcinoma metastatic | 11.16 | 10.83 | 17 | 40398 | 3312 | 32469799 |
Post thrombotic syndrome | 11.15 | 10.83 | 5 | 40410 | 161 | 32472950 |
Skin cancer | 11.10 | 10.83 | 30 | 40385 | 8820 | 32464291 |
Tubulointerstitial nephritis | 11.08 | 10.83 | 51 | 40364 | 19526 | 32453585 |
Leukopenia | 11.05 | 10.83 | 38 | 40377 | 60084 | 32413027 |
Transient ischaemic attack | 10.96 | 10.83 | 62 | 40353 | 25732 | 32447379 |
Scan myocardial perfusion abnormal | 10.88 | 10.83 | 4 | 40411 | 76 | 32473035 |
Source | Code | Description |
---|---|---|
ATC | C09CA04 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain |
ATC | C09DA04 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics |
ATC | C09DB05 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and calcium channel blockers |
ATC | C09DX07 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs), other combinations |
FDA MoA | N0000000070 | Angiotensin 2 Receptor Antagonists |
FDA EPC | N0000175561 | Angiotensin 2 Receptor Blocker |
MeSH PA | D047228 | Angiotensin II Type 1 Receptor Blockers |
MeSH PA | D057911 | Angiotensin Receptor Antagonists |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
CHEBI has role | CHEBI:35674 | antihypertensive |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:61016 | angiotensin receptor antagonists |
CHEBI has role | CHEBI:78298 | environmental contaminants |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Diabetic renal disease | indication | 127013003 | |
Chronic heart failure | off-label use | 48447003 | |
Atrial fibrillation | off-label use | 49436004 | DOID:0060224 |
Diastolic heart failure | off-label use | 418304008 | DOID:9775 |
Nondiabetic Proteinuric Nephropathy | off-label use | ||
Anuria | contraindication | 2472002 | DOID:2983 |
Hypercholesterolemia | contraindication | 13644009 | |
Hyperkalemia | contraindication | 14140009 | |
Secondary angle-closure glaucoma | contraindication | 21571006 | |
Hypovolemia | contraindication | 28560003 | |
Dehydration | contraindication | 34095006 | |
Hyperuricemia | contraindication | 35885006 | DOID:1920 |
Angioedema | contraindication | 41291007 | DOID:1558 |
Hypokalemia | contraindication | 43339004 | |
Low blood pressure | contraindication | 45007003 | |
Systemic lupus erythematosus | contraindication | 55464009 | DOID:9074 |
Sympathectomy | contraindication | 57071006 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Hyperparathyroidism | contraindication | 66999008 | DOID:13543 |
Hypochloremic alkalosis | contraindication | 70134007 | |
Hepatic coma | contraindication | 72836002 | DOID:12550 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyponatremia | contraindication | 89627008 | |
Gout | contraindication | 90560007 | DOID:13189 |
Disorder of muscle | contraindication | 129565002 | DOID:423 |
Hypomagnesemia | contraindication | 190855004 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Rhabdomyolysis | contraindication | 240131006 | |
Neonatal hyperbilirubinemia | contraindication | 281610001 | |
Pregnancy, function | contraindication | 289908002 | |
Renal artery stenosis | contraindication | 302233006 | |
Azotemia | contraindication | 445009001 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.37 | acidic |
pKa2 | 3.63 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Type-1 angiotensin II receptor | GPCR | ANTAGONIST | Ki | 9.10 | CHEMBL | CHEMBL | |||
Endothelin-1 receptor | GPCR | Ki | 5 | CHEMBL | |||||
Sodium/bile acid cotransporter | Transporter | INHIBITOR | Ki | 4.92 | IUPHAR | ||||
Type-1B angiotensin II receptor | GPCR | Ki | 9.10 | CHEMBL | |||||
Angiotensin II receptor (AT-1) type-1 | GPCR | IC50 | 8.89 | CHEMBL | |||||
Angiotensin II receptor | GPCR | IC50 | 8.89 | CHEMBL |
ID | Source |
---|---|
4021071 | VUID |
N0000148533 | NUI |
D00523 | KEGG_DRUG |
329055-23-4 | SECONDARY_CAS_RN |
4021071 | VANDF |
C0288171 | UMLSCUI |
CHEBI:5959 | CHEBI |
CHEMBL1513 | ChEMBL_ID |
D000077405 | MESH_DESCRIPTOR_UI |
DB01029 | DRUGBANK_ID |
3749 | PUBCHEM_CID |
589 | IUPHAR_LIGAND_ID |
7229 | INN_ID |
J0E2756Z7N | UNII |
83818 | RXNORM |
4917 | MMSL |
52343 | MMSL |
d04222 | MMSL |
006921 | NDDF |
108585000 | SNOMEDCT_US |
386877005 | SNOMEDCT_US |
734504000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Avapro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0024-5850 | TABLET, FILM COATED | 75 mg | ORAL | NDA | 29 sections |
Avapro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0024-5851 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 29 sections |
Avapro | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0024-5852 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 29 sections |
Avalide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0024-5855 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 30 sections |
Avalide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0024-5856 | TABLET, FILM COATED | 300 mg | ORAL | NDA | 30 sections |
Irbesartan and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0054-0254 | TABLET | 150 mg | ORAL | ANDA | 28 sections |
Irbesartan and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0054-0255 | TABLET | 300 mg | ORAL | ANDA | 28 sections |
Irbesartan and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-8232 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 28 sections |
Irbesartan and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-8238 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 28 sections |
Irbesartan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1040 | TABLET, FILM COATED | 75 mg | ORAL | NDA AUTHORIZED GENERIC | 27 sections |
Irbesartan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1041 | TABLET, FILM COATED | 150 mg | ORAL | NDA AUTHORIZED GENERIC | 27 sections |
Irbesartan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0955-1042 | TABLET, FILM COATED | 300 mg | ORAL | NDA AUTHORIZED GENERIC | 27 sections |
Irbesartan and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0955-1045 | TABLET, FILM COATED | 150 mg | ORAL | NDA AUTHORIZED GENERIC | 29 sections |
Irbesartan and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0955-1046 | TABLET, FILM COATED | 300 mg | ORAL | NDA AUTHORIZED GENERIC | 29 sections |
Irbesartan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-212 | TABLET | 75 mg | ORAL | ANDA | 23 sections |
Irbesartan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-213 | TABLET | 150 mg | ORAL | ANDA | 23 sections |
Irbesartan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-214 | TABLET | 300 mg | ORAL | ANDA | 23 sections |
Irbesartan and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 29300-215 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 26 sections |
Irbesartan and Hydrochlorothiazide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 29300-216 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 26 sections |
Irbesartan | Human Prescription Drug Label | 1 | 31722-160 | TABLET | 75 mg | ORAL | ANDA | 27 sections |
Irbesartan | Human Prescription Drug Label | 1 | 31722-161 | TABLET | 150 mg | ORAL | ANDA | 27 sections |
Irbesartan | Human Prescription Drug Label | 1 | 31722-162 | TABLET | 300 mg | ORAL | ANDA | 27 sections |
Irbesartan | Human Prescription Drug Label | 1 | 31722-729 | TABLET | 75 mg | ORAL | ANDA | 27 sections |
Irbesartan | Human Prescription Drug Label | 1 | 31722-730 | TABLET | 150 mg | ORAL | ANDA | 27 sections |
Irbesartan | Human Prescription Drug Label | 1 | 31722-731 | TABLET | 300 mg | ORAL | ANDA | 27 sections |
Irbesartan | Human Prescription Drug Label | 1 | 33342-047 | TABLET | 75 mg | ORAL | ANDA | 26 sections |
Irbesartan | Human Prescription Drug Label | 1 | 33342-048 | TABLET | 150 mg | ORAL | ANDA | 26 sections |
Irbesartan | Human Prescription Drug Label | 1 | 33342-049 | TABLET | 300 mg | ORAL | ANDA | 26 sections |
Irbesartan and Hydrochlorothiazide | Human Prescription Drug Label | 2 | 33342-057 | TABLET, FILM COATED | 150 mg | ORAL | ANDA | 23 sections |
Irbesartan and Hydrochlorothiazide | Human Prescription Drug Label | 2 | 33342-058 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 23 sections |